Mostrar el registro sencillo del ítem

dc.contributor.authorValdés, Sergio
dc.contributor.authorOlveira-Fuster, Gabriel María 
dc.contributor.authorSánchez-Torralvo, Francisco José
dc.contributor.authorVázquez-Pedreño, Luis
dc.contributor.authorGonzalo-Marín, Montserrat
dc.contributor.authorTapia Guerrero, María José
dc.contributor.authorLima, Fuensanta
dc.contributor.authorGarcía-Fuentes, Eduardo
dc.contributor.authorGarcía, Pilar
dc.contributor.authorMoreno-Ruiz, Francisco Javier 
dc.contributor.authorRodríguez-Cañete, Alberto 
dc.date.accessioned2022-06-07T12:05:57Z
dc.date.available2022-06-07T12:05:57Z
dc.date.issued2022-04-11
dc.identifier.citationSánchez-Torralvo FJ, Vázquez-Pedreño L, Gonzalo-Marín M, Tapia MJ, Lima F, García-Fuentes E, García P, Moreno-Ruiz J, Rodríguez-Cañete A, Valdés S, Olveira G. Endoscopic Intragastric Injection of Botulinum Toxin A in Obese Patients Accelerates Weight Loss after Bariatric Surgery: Follow-Up of a Randomised Controlled Trial (IntraTox Study). Journal of Clinical Medicine. 2022; 11(8):2126. https://doi.org/10.3390/jcm11082126es_ES
dc.identifier.urihttps://hdl.handle.net/10630/24309
dc.description.abstractIntragastric injection of botulinum toxin A (BT-A) has been shown to be effective for weight loss up to six months after administration, according to previous studies. Our objective was to determine, in patients on bariatric surgery waiting lists, the effect of BT-A on weight loss in the pre- and postoperative period and to analyse if there are different responses based on Body Mass Index (BMI). Methods: We performed a follow-up analysis of the IntraTox study, which included 46 patients on bariatric surgery waiting lists in a single-centre, randomised, double-blind, placebo-controlled clinical trial. The treatment group received intragastric BT-A, whereas the control group received physiological saline solution. The one-time procedure was performed at the time of diagnostic endoscopy 7–8 months before surgery. Weight loss was evaluated at admission and after 4 and 12 weeks from the bariatric surgery. Our analysis was stratified by BMI at randomisation. Results: weight loss percentage on the day of surgery, with respect to the initial visit, was −4.5 ± 3.9% for the control group vs. −7.6 ± 4.2%, for the treatment group (p = 0.013). Weight loss percentage tended to remain greater in the treatment group one month after the intervention (−12.7 ± 4.7% vs. −15.2 ± 4.6%, p = 0.07) and become similar three months after (−21.6 ± 4.7% vs. −21.6 ± 4.6%). After stratifying by BMI, only patients with BMI over 50 kg/m2 allocated to the treatment group obtained a greater weight loss at the end of the trial, the day of surgery, and one month after, compared with the placebo group (−4.9 ± 4.9%, −10.8 ± 5.3% and −17.1 ± 3.8% vs. −0.1 ± 2.6%, −4.3 ± 3.2% and −12.8 ± 4.1%, respectively (p < 0.05). Conclusions: intragastric injection of BT-A is effective to achieve significant weight loss, especially in extreme obesity. Its use before bariatric surgery enhances perioperative weight loss.es_ES
dc.description.sponsorshipMerz Pharma (Frankfurt am Main, Germany) collaborated with a non-restricted grant. The study was co-funded by the Sociedad Andaluza de Endocrinología, Diabetes y Nutrición (SAEDYN) and the Sociedad Andaluza de Nutrición, Clínica y Dietética (SANCYD). This research was supported by the Plataforma Española de Investigación Clínica y Ensayos Clínicos, SCReN (Spanish Clinical Research Network), funded by ISCIII-Subdirección General de Evaluación y Fomento de la Investigación, through the projects PT13/0002/0020 and PT17/0020, integrated in the Plan Estatal de I+D+I 2013-2016 and co-funded by the European Regional Development Fund (ERDF). Partial funding for open access charge: Universidad de Málagaes_ES
dc.language.isospaes_ES
dc.publisherIOAP-MPDIes_ES
dc.rightsinfo:eu-repo/semantics/openAccesses_ES
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.subjectObesidades_ES
dc.subject.otherObesityes_ES
dc.subject.otherBotulinum toxines_ES
dc.subject.otherWeight losses_ES
dc.subject.otherEndoscopyes_ES
dc.subject.otherBariatric surgeryes_ES
dc.titleEndoscopic Intragastric Injection of Botulinum Toxin A in Obese Patients Accelerates Weight Loss after Bariatric Surgery: Follow-Up of a Randomised Controlled Trial (IntraTox Study)es_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.centroFacultad de Medicinaes_ES
dc.identifier.doihttps://doi.org/10.3390/jcm11082126
dc.rights.ccAtribución 4.0 Internacional*


Ficheros en el ítem

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

Atribución 4.0 Internacional
Excepto si se señala otra cosa, la licencia del ítem se describe como Atribución 4.0 Internacional